Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Neuroscience Right
  3. Emgality (galcanezumab-gnlm) injection Right
  4. How is Emgality® (galcanezumab-gnlm) metabolized and eliminated?
Search Emgality (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How is Emgality® (galcanezumab-gnlm) metabolized and eliminated?

Emgality (galcanezumab) is expected to be degraded via catabolic pathways in the same manner as endogenous IgG.

US_cFAQ_GLC003_METABOLISM_ELIMINATION
US_cFAQ_GLC003_METABOLISM_ELIMINATION
en-US

Pharmacokinetic (PK) Characteristics of Galcanezumab Metabolism and Elimination

Galcanezumab is an immunoglobulin G (subclass 4) monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous immunoglobulin G.1-3

As such, it is not expected to

  • inhibit metabolic pathways or induce enzymatic pathways
  • be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, and
  • produce any active metabolites.2,4,5

Based on a population PK analysis, the apparent clearance was approximately 0.008 L/h with 34% interindividual variability and was similar in healthy subjects and patients with chronic or episodic migraine.1,2

Enclosed Prescribing Information

EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

2Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780

3Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug–drug interactions of new anti-migraine drugs—lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1180. https://doi.org/10.3390/pharmaceutics12121180

4Data on file, Eli Lilly and Company and/or one of its subsidiaries.

5Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. https://doi.org/10.1002/jps.20178

Date of Last Review: March 06, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly